Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer

Journal of Clinical Oncology

Volumn 13, Issue 11, 1995, Pages 2722-2730

  Weber, Barbara L ^a   Vogel, Charles ^b   Jones, Stephen ^b   Harvey, Harold ^b   Hutchins, Laura ^b   Bigley, Joseph ^b   Hohneker, John ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

NAVELBINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; FEMALE; GRANULOCYTOPENIA; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEPSIS; TREATMENT OUTCOME;

EID: 0028848191     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1995.13.11.2722     Document Type: Article

References (23)

1. Binet S, Fellous A, Lataste H, et al: In situ analysis of the action of Navelbine on various types of microtubules using immunofluorescence. Semin Oncol 16:5-8, 1989 (suppl 4)
2. Fellous A, Ohayon R, Vacassin T, et al: Biochemical effects of Navelbine on tubulin and assorted proteins. Semin Oncol 16:9-14, 1989 (suppl 4)
3. Besenval M, Delgado M, Demarez PP, et al: Safety and tolerance of Navelbine in phase II clinical studies. Semin Oncol 16:37-40, 1989 (suppl 4)
4. Fumoleau P, Delgado FM, Delozier T, et al: Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 11:1245-1252, 1993
5. Romero A, Rabinovich MG, Vallejo CT, et al: Vinorelbine as first-line chemotherapy for metastatic breast carcinoma. J Clin Oncol 12:336-341, 1994
6. Canobbio L, Boccardo F, Pastorino G, et al: Phase-II study of Navelbine in advanced breast cancer. Semin Oncol 16:33-36, 1989 (suppl 4)
7. Hohneker J: A summary of vinorelbine (Navelbine) safety data from North American clinical trials. Semin Oncol 21:42-47, 1994 (suppl 10)
8. Deconti RC, Creey WA: Clinical aspects of the dimeric catharanthus alkaloids, in Taylor WR, Famsworth NR (eds): The Cataranthus Alkaloids, Botany, Chemistry, Pharmacology and Clinical Use. New York, NY, Dekker, 1975, pp 237-278
9. Potier P: The synthesis of Navelbine prototype of a new series of vinblastine derivatives. Semin Oncol 16:2-4, 1989 (suppl 4)
10. Rahmani R, Martin M, Barbet J, et al: Radioimmunoassay and preliminary pharmacokinetics in rats of 5′ nor-anhydrovinblastine (Navelbine). Cancer Res 44:5609-5613, 1984
11. Cros S, Wright M, Morimoto M, et al: Experimental antitumor activity of Navelbine. Semin Oncol 16:15-20, 1989
12. Mathe G, Reizenstein P: Phase I pharmacologic study of a new vinca alkaloid: Navelbine. Cancer Lett 27:285-293, 1985
13. Rittenberg CN, Rehmeyer TA, Gralla RJ, et al: Reducing venous irritation in chemotherapy administration: An investigation during the new agent testing of Navelbine. Presented at the Sixth International Symposium on Supportive Care in Cancer, March 2-5. 1994 (abstr)
14. Henderson IC: Chemotherapy for metastatic disease, in Harris JR, Hellman S, Henderson IC, Kinne DW (eds): Breast Disease. Philadelphia, PA, Lippincott, 1991, pp 604-665
15. Holmes FA, Walters RS, Theriault RL, et al: Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83:1797-1805, 1991
16. Holmes FA, Valero V, Theriault RL, et al: Phase II trial of Taxol (T) in metastatic breast cancer (MBC) refractory to multiple prior treatments. Proc Am Soc Clin Oncol 12:94, 1993 (abstr 178)
17. Munzone E, Capri G, Demicheli R, et al: Activity of Taxol (T) by 3 h infusion in breast cancer patients (pts) with clinical resistance to anthracyclines (A). Eur J Cancer 29A:S79, 1993 (suppl 6, abstr 413)
18. Nabholtz JM, Gelmon K, Bontenbal M, et al: Randomized trial of two doses of Taxol in metastatic breast cancer: An interim analysis. Proc Am Soc Clin Oncol 12:60, 1993 (abstr 42)
19. Seidman A, Crown J, Reichman B, et al: Lack of clinical cross-resistance of Taxol (T) with anthracycline (A) in the treatment of metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 12:63, 1993 (abstr 53)
20. Uziely B, Delaflor-Weiss E, Russel C, et al: Refractory breast cancer treatment with Taxol: Correlations with baseline immunohistochemistry for p-glycoprotein (Pgp). Eur J Cancer 29A:S81, 1993 (suppl 6, abstr 423)
21. Wilson WH, Berg S, Bryant G: Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: A phase I/II trial of 96-hour infusion. J Clin Oncol 12:1621-1629, 1994
22. Reichman BS, Seidman AD, Crown JPA, et al: Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 11:1943-1951, 1993
23. Henderson IC: Chemotherapy of breast cancer. Cancer 51:2553-2559, 1983